OpGen - Spezialist gegen antibiotikaresistente Infektionen (Seite 36)
eröffnet am 13.08.15 09:48:54 von
neuester Beitrag 10.11.23 14:21:39 von
neuester Beitrag 10.11.23 14:21:39 von
Beiträge: 402
ID: 1.217.076
ID: 1.217.076
Aufrufe heute: 0
Gesamt: 36.933
Gesamt: 36.933
Aktive User: 0
ISIN: US68373L4068 · WKN: A3D38S · Symbol: 650
0,4620
EUR
0,00 %
0,0000 EUR
Letzter Kurs 26.04.24 Stuttgart
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 0,5922 | +44,44 | |
| 6,8660 | +44,27 | |
| 11,690 | +40,84 | |
| 0,7000 | +36,69 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,6900 | -14,50 | |
| 2,8150 | -15,21 | |
| 7,6100 | -17,20 | |
| 1,6100 | -18,27 | |
| 2,1200 | -21,77 |
Beitrag zu dieser Diskussion schreiben
Feedback
+ 23 % auf Tradegate.
Und das beste kommt noch (die Nachrichten am 10. und voraussichtlich 25. März).
Hammer-Aktie und von vielen noch unentdeckt.
Und das beste kommt noch (die Nachrichten am 10. und voraussichtlich 25. März).
Hammer-Aktie und von vielen noch unentdeckt.
Das Unternehmen, das von OpGen geschluckt wird, muss der Fusion natürlich auch zustimmen. 
Curetis to Hold Extraordinary General Meeting on March 10, 2020
Curetis N.V. will hold the EGM on Tuesday, March 10, 2020, at Steigenberger Airport Hotel, Stationsplein Zuid - West 951, 1117 CE Schiphol - Oost/Amsterdam, the Netherlands. The meeting is scheduled to commence at 01:00pm CET; local registration starts at 12:30pm CET.
In addition, Curetis N.V. will be offering electronic pre-voting from Wednesday, February 12, 2020, at 08:00am CET to Tuesday, March 3, 2020, 05:30pm CET at www.abnamro.com/evoting.
A copy of the convening notice for the EGM, including a description of the formalities to participate in the EGM, and a shareholder circular explaining the proposed resolutions of the EGM in more detail, are available at https://curetis.com/investors/#corporate-governance.
Primary resolutions on the agenda of the EGM relate to the Implementation Agreement (the "Implementation Agreement") with OpGen and Crystal GmbH, a wholly-owned subsidiary of OpGen incorporated in Germany, which was announced September 4, 2019. Under the Implementation Agreement, the Company and OpGen have agreed on the terms of the Transaction (the "Transaction") under which Curetis GmbH, owning all of the Company’s group business, will be acquired by OpGen in exchange for the issuance of new OpGen shares to the Company, and the Company’s business will be continued by OpGen.
The Transaction is subject to approval of the shareholders and debt holders of the Company and Curetis GmbH, as well as the stockholders of OpGen and debt holders of OpGen.
Following the Transaction, it is intended that the Company will be dissolved (the "Dissolution”) and that OpGen shares issued to the Company will be distributed to the shareholders as a liquidation distribution, to the extent possible, in advance pro rata to each share held by them on the Distribution Record Date (the “Distribution”, see paragraph 4 of the shareholder circular for more details).
During the EGM, the shareholders will, among others, be asked to approve:
(i) the Transaction in accordance with Section 2:107a of the Dutch Civil Code;
(ii) the resolution to effect the Dissolution of Curetis N.V.;
(iii) the Distribution of OpGen shares received as consideration to Curetis N.V. shareholders
(iv) the establishment of remuneration of the liquidators and the supervisory directors of Curetis N.V., respectively, for the performance of their duties during the liquidation process;
(v) the granting of discharge to the managing directors and supervisory directors of Curetis N.V., respectively, in respect of the performance of their duties and
(vi) the appointment of Curetis GmbH as custodian of the books and records of Curetis N.V. in accordance with article 2:24 of the Dutch Civil Code.
If approved by the EGM and finalized, the overall result of the Transaction, the Dissolution and the Distribution will be that the investment of shareholders of the Company holding shares in the Company on the Distribution Record Date is effectively transformed from a holding of shares in the Company to a holding of OpGen Shares, listed on NASDAQ.
https://www.globenewswire.com/news-release/2020/01/27/197519…
Curetis to Hold Extraordinary General Meeting on March 10, 2020
Curetis N.V. will hold the EGM on Tuesday, March 10, 2020, at Steigenberger Airport Hotel, Stationsplein Zuid - West 951, 1117 CE Schiphol - Oost/Amsterdam, the Netherlands. The meeting is scheduled to commence at 01:00pm CET; local registration starts at 12:30pm CET.
In addition, Curetis N.V. will be offering electronic pre-voting from Wednesday, February 12, 2020, at 08:00am CET to Tuesday, March 3, 2020, 05:30pm CET at www.abnamro.com/evoting.
A copy of the convening notice for the EGM, including a description of the formalities to participate in the EGM, and a shareholder circular explaining the proposed resolutions of the EGM in more detail, are available at https://curetis.com/investors/#corporate-governance.
Primary resolutions on the agenda of the EGM relate to the Implementation Agreement (the "Implementation Agreement") with OpGen and Crystal GmbH, a wholly-owned subsidiary of OpGen incorporated in Germany, which was announced September 4, 2019. Under the Implementation Agreement, the Company and OpGen have agreed on the terms of the Transaction (the "Transaction") under which Curetis GmbH, owning all of the Company’s group business, will be acquired by OpGen in exchange for the issuance of new OpGen shares to the Company, and the Company’s business will be continued by OpGen.
The Transaction is subject to approval of the shareholders and debt holders of the Company and Curetis GmbH, as well as the stockholders of OpGen and debt holders of OpGen.
Following the Transaction, it is intended that the Company will be dissolved (the "Dissolution”) and that OpGen shares issued to the Company will be distributed to the shareholders as a liquidation distribution, to the extent possible, in advance pro rata to each share held by them on the Distribution Record Date (the “Distribution”, see paragraph 4 of the shareholder circular for more details).
During the EGM, the shareholders will, among others, be asked to approve:
(i) the Transaction in accordance with Section 2:107a of the Dutch Civil Code;
(ii) the resolution to effect the Dissolution of Curetis N.V.;
(iii) the Distribution of OpGen shares received as consideration to Curetis N.V. shareholders
(iv) the establishment of remuneration of the liquidators and the supervisory directors of Curetis N.V., respectively, for the performance of their duties during the liquidation process;
(v) the granting of discharge to the managing directors and supervisory directors of Curetis N.V., respectively, in respect of the performance of their duties and
(vi) the appointment of Curetis GmbH as custodian of the books and records of Curetis N.V. in accordance with article 2:24 of the Dutch Civil Code.
If approved by the EGM and finalized, the overall result of the Transaction, the Dissolution and the Distribution will be that the investment of shareholders of the Company holding shares in the Company on the Distribution Record Date is effectively transformed from a holding of shares in the Company to a holding of OpGen Shares, listed on NASDAQ.
https://www.globenewswire.com/news-release/2020/01/27/197519…
Antwort auf Beitrag Nr.: 62.925.887 von Malecon am 08.03.20 22:41:39
Link
https://www.welt.de/wirtschaft/article206339325/Coronavirus…
Nicht weniger spannend als der Fusions-Termin am 10. März ist auch die Zahlenpräsentation voraussichtlich am 25. März.
Ein wichtiger Monat für die Aktie.
Ein wichtiger Monat für die Aktie.
Antwort auf Beitrag Nr.: 62.924.540 von Malecon am 08.03.20 19:15:32Danke schön 👍
Trading Spotlight
Zur Erinnerung die Erwartungen von Analysten aus dem Monat Dezember für das Jahr 2020:
Combined company revenue set to double in 2020
Guidance is for combined company revenue to increase from $5–6m in 2019 to $10–15m in 2020.
Valuation: $46.9m or $8.39 per share
We have adjusted our valuation to $46.9m or $8.39 per basic share
https://www.edisongroup.com/publication/shareholder-votes-on…
Combined company revenue set to double in 2020
Guidance is for combined company revenue to increase from $5–6m in 2019 to $10–15m in 2020.
Valuation: $46.9m or $8.39 per share
We have adjusted our valuation to $46.9m or $8.39 per basic share
https://www.edisongroup.com/publication/shareholder-votes-on…
Danke, das habe ich geahnt. Morgen wird massiv nachgekauft.
Antwort auf Beitrag Nr.: 62.924.183 von Growth2012 am 08.03.20 18:31:17Also eventuell vielleicht mögliches Kursziel hier ~ USD 25 mit guten Daten? Klingt sehr spannend 🤔🧐
von drüben auf Yahoo folgendes zum Fusion & aussichten
Dienstag nach Börsenschluß sollte es "first merger news geben" " The merger will eliminate the uncertainty of whether it happens or not and that alone should stabilize the stock at around $3.50. The question is when catalyst are announced - kit sales in Europe & China, US approval on kit sales, Curetis BLA projections, and OPGN's FDA approval what happens. Obviously, the stock will rise and the exit of sorting will allow it to more easily, but rise by how much? Also, the next FDA filing for UTI is the "big" one with potential revenue of $100mm so OPGN FDA#1 approval increases the chance of OPGN FDA#2 approval With 11.75mm shares o/s post close this could move up significantly very quickly. Also, the merger will not be voted down. If the votes are not there the meeting will be cancelled. Some quick math: Assume all catalyst project $50mm in revenue and a 40% operating margin = Profit Margin of $20mm. Divide $20mm by 11.75mm = $1.7 eps x 15 = $25.53 s/p.
https://finance.yahoo.com/quote/OPGN/community?p=OPGN
...hoffen wir das beste 💹👏💲
Dienstag nach Börsenschluß sollte es "first merger news geben" " The merger will eliminate the uncertainty of whether it happens or not and that alone should stabilize the stock at around $3.50. The question is when catalyst are announced - kit sales in Europe & China, US approval on kit sales, Curetis BLA projections, and OPGN's FDA approval what happens. Obviously, the stock will rise and the exit of sorting will allow it to more easily, but rise by how much? Also, the next FDA filing for UTI is the "big" one with potential revenue of $100mm so OPGN FDA#1 approval increases the chance of OPGN FDA#2 approval With 11.75mm shares o/s post close this could move up significantly very quickly. Also, the merger will not be voted down. If the votes are not there the meeting will be cancelled. Some quick math: Assume all catalyst project $50mm in revenue and a 40% operating margin = Profit Margin of $20mm. Divide $20mm by 11.75mm = $1.7 eps x 15 = $25.53 s/p.
https://finance.yahoo.com/quote/OPGN/community?p=OPGN
...hoffen wir das beste 💹👏💲
Antwort auf Beitrag Nr.: 62.922.410 von Malecon am 08.03.20 14:09:52OpGen and Curetis entered into a definitive agreement to combine businesses on September 4, 2019. The closing of the transaction under such definitive agreement has not yet occurred and is subject to a number of significant closing conditions, including receipt of approval from the stockholders of OpGen, Inc. and the shareholders of Curetis, N.V. To this end, OpGen filed and furnished to its stockholders a proxy statement/prospectus and a notice of special meeting of OpGen stockholders to be held on March 10, 2020 to approve the business combination with Curetis. On the same day at 1:00pm CET, Curetis will host its extraordinary shareholder meeting with the objective of seeking approval from its shareholders for the planned business combination with OpGen.
https://ir.opgen.com/news-releases/news-release-details/opge…
...24Std (sprich ein komplette Handels-session nach der approval am 11.3) wissen wir alle mehr
https://ir.opgen.com/news-releases/news-release-details/opge…
...24Std (sprich ein komplette Handels-session nach der approval am 11.3) wissen wir alle mehr
Durchsuchen
